Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Vipul Jairath, Reena Khanna & Brian G. Feagan. (2017) Alicaforsen for the treatment of inflammatory bowel disease. Expert Opinion on Investigational Drugs 26:8, pages 991-997.
Read now
Read now
Ben Vainer, Thomas Horn & Ole Haagen Nielsen. (2006) Colonic epithelial cell expression of ICAM-1 relates to loss of surface continuity: A comparative study of inflammatory bowel disease and colonic neoplasms. Scandinavian Journal of Gastroenterology 41:3, pages 318-325.
Read now
Read now
Articles from other publishers (12)
Ben VAINER. (2010) Intercellular adhesion molecule-1 (ICAM-1) in ulcerative colitis: presence, visualization, and significance. APMIS 118, pages 1-46.
Crossref
Crossref
G. Tsiolakidou, I.E. Koutroubakis, M. Tzardi & E.A. Kouroumalis. (2008) Increased expression of VEGF and CD146 in patients with inflammatory bowel disease. Digestive and Liver Disease 40:8, pages 673-679.
Crossref
Crossref
Livija Deban, Carmen Correale, Stefania Vetrano, Alberto Malesci & Silvio Danese. (2008) Multiple Pathogenic Roles of Microvasculature in Inflammatory Bowel Disease: A Jack of All Trades. The American Journal of Pathology 172:6, pages 1457-1466.
Crossref
Crossref
Ioannis E. Koutroubakis, Georgia Tsiolakidou, Konstantinos Karmiris & Elias A. Kouroumalis. (2006) Role of angiogenesis in inflammatory bowel disease. Inflammatory Bowel Diseases 12:6, pages 515-523.
Crossref
Crossref
S. J. H. VAN DEVENTER, M. K. WEDEL, B. F. BAKER, S. XIA, E. CHUANG & P. B. MINER. (2006) A Phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Alimentary Pharmacology and Therapeutics 23:10, pages 1415-1425.
Crossref
Crossref
P. B. MINER, R. S. GEARY, J. MATSON, E. CHUANG, S. XIA, B. F. BAKER & M. K. WEDEL. (2006) Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Alimentary Pharmacology and Therapeutics 23:10, pages 1427-1434.
Crossref
Crossref
P. B. MINER, M. K. WEDEL, S. XIA & B. F. BAKER. (2006) Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Alimentary Pharmacology and Therapeutics 23:10, pages 1403-1413.
Crossref
Crossref
Edward E. S. Nieuwenhuis & Richard S. Blumberg. 2006. Immune Mechanisms in Inflammatory Bowel Disease. Immune Mechanisms in Inflammatory Bowel Disease
108
116
.
P. Rutgeerts, S. Van Deventer & S. Schreiber. (2003) The expanding role of biological agents in the treatment of inflammatory bowel disease - focus on selective adhesion molecule inhibition. Alimentary Pharmacology & Therapeutics 17:12, pages 1435-1450.
Crossref
Crossref
Mario Roselli, Fiorella Guadagni, Francesca Martini, Antonella Spila, Sabrina Mariotti, Roberta D’Alessandro, Simona Aloe, Pier Paolo Gazzaniga, Stefania Basili, Maurizio Cosimelli & Patrizia Ferroni. (2003) Association between Serum Carcinoembryonic Antigen and Endothelial Cell Adhesion Molecules in Colorectal Cancer. Oncology 65:2, pages 132-138.
Crossref
Crossref
A. Tarnawski, R. Pai, R. Itani & F.A. Wyle. (1999) The Antacid Talcid Adsorbs and Neutralizes All Proteins Secreted by <i>H. pylori</i> Including VacA Cytotoxin: A New Mechanism for Its Ulcer-Healing Action?. Digestion 60:5, pages 449-455.
Crossref
Crossref
Yoshimasa Yamamoto, Amal Hakki, Herman Friedman, Sachie Okubo, Tadakatsu Shimamura, Paul S. Hoffman & Jean-François Rossignol. (1999) Nitazoxanide, a Nitrothiazolide Antiparasitic Drug, Is an Anti-<i>Helicobacter pylori</i> Agent with Anti-Vacuolating Toxin Activity. Chemotherapy 45:4, pages 303-312.
Crossref
Crossref